Unlocking ATPase6V0A2 as A Drug Target (G23545)

Target Name: ATP6V0A2

NCBI ID: G23545

ATP6V0A2

Unlocking ATPase6V0A2 as A Drug Target

Unlocking the Potential of ATPase6V0A2 as a Drug Target: Unraveling the Role of ATPase in H+ Transport and Lysosomal Functions

ATP (adenylyl triphosphate) is a ubiquitous molecule that plays a vital role in various cellular processes, including energy generation, signaling, and cell signaling pathways. One of the well-known functions of ATP is its ability to transport proton channels, also known as ATP-dependent proton channels or H+-ATPase, allowing it to regulate the concentration of protons in the cytosol. The H+-ATPase, ATPase6V0A2, is a subunit of this transporter that has been identified as a potential drug target or biomarker for various diseases, including neurodegenerative disorders, cancer, and urologic diseases.

ATPase6V0A2: Structure and Function

The H+-ATPase is a transmembrane protein that consists of two main subunits, ATPase (also known as ATP-activating protonase or H+-ATPase) and the N-terminal transmembrane region (TMD). The ATPase subunit consists of a catalytic active site, a regulatory region, and a C-terminal region that contains a unique protein-protein interaction (PPI) domain.

ATPase6V0A2 is a 21-kDa protein that is expressed in various cell types, including neurons, muscle cells, and red blood cells. It is primarily localized to the cytosol, where it is responsible for regulating the concentration of protons by ATP-dependent proton channels. These channels allow the cytosol to export protons to the lysosome, where they are targeted for degradation or further processing.

ATPase6V0A2 is a critical regulator of cellular pH and plays a crucial role in maintaining the proper balance of protons in the cytosol. It has been shown to modulate various cellular processes, including cell signaling, DNA replication, and neurotransmission.

Drug Target Potential

The potential of ATPase6V0A2 as a drug target is based on its unique function in regulating protons in the cytosol and its involvement in various cellular processes. Several studies have demonstrated that modulating the activity of ATPase6V0A2 can lead to therapeutic effects in various diseases.

1. Neurodegenerative Disorders:

Neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of debilitating symptoms. These disorders are often associated with the misfolding of proteins and the formation of neurofibrillary tangles, which are thought to contribute to the degenerative process.

Several studies have suggested that misfolded proteins, including the neurotransmitter acetylcholine, can accumulate in the cytosol and contribute to the pathological changes in neurodegenerative disorders. Modulation of ATPase6V0A2 activity, through its role in regulating protons in the cytosol, may provide a new therapeutic approach for the treatment of these disorders.

1. Cancer:

Cancer is a heterogeneous disease that affects various cell types and can inflict significant morbidity and mortality. The regulation of cellular pH is a critical aspect of cancer development, as it plays a significant role in the regulation of cell cycle progression, apoptosis, and angiogenesis.

Several studies have shown that cancer cells can alter the activity of ATPase6V0A2, leading to changes in cellular pH and the regulation of various cellular processes. These changes can contribute to the maintenance of the cell's survival and the development of resistance to chemotherapy.

1. Urologic Disorders:

Urologic disorders, such as urinary tract infection (UTI) and kidney stones, are characterized by the accumulation of particles in the urine that can cause significant discomfort and medical complications. These disorders are often associated with the regulation of water transport and the balance of electrolytes, including protons.

Several studies have suggested that alterations in the activity of ATPase6V0A2 can contribute to the development and progression of urologic disorders. For example, UTIs have been associated with changes in the concentration of protons in the urine, which may contribute to the risk of complications. Modulation of ATPase6V0A2 activity, through its role in regulating protons in the cytosol, may provide new therapeutic approaches for the treatment of urologic disorders.

Conclusion

ATPase6V0A2 is a protein that plays a critical role in regulating the concentration of protons in the cytosol and its involvement in various cellular processes makes it an attractive drug target or biomarker for various diseases. The potential of modulating the activity of ATPase6V0A2 through its role in ATP-dependent proton channels is being investigated as a new therapeutic approach for the treatment of neurodegenerative disorders, cancer, and urologic disorders. Further research is needed to fully understand the mechanisms of ATPase6V0A2's role in these diseases and to develop safe and effective therapies that can modulate its activity.

Protein Name: ATPase H+ Transporting V0 Subunit A2

Functions: Subunit of the V0 complex of vacuolar(H+)-ATPase (V-ATPase), a multisubunit enzyme composed of a peripheral complex (V1) that hydrolyzes ATP and a membrane integral complex (V0) that translocates protons (By similarity). V-ATPase is responsible for acidifying and maintaining the pH of intracellular compartments and in some cell types, is targeted to the plasma membrane, where it is responsible for acidifying the extracellular environment (By similarity). Essential component of the endosomal pH-sensing machinery (PubMed:16415858). May play a role in maintaining the Golgi functions, such as glycosylation maturation, by controlling the Golgi pH (PubMed:18157129). In aerobic conditions, involved in intracellular iron homeostasis, thus triggering the activity of Fe(2+) prolyl hydroxylase (PHD) enzymes, and leading to HIF1A hydroxylation and subsequent proteasomal degradation (PubMed:28296633)

The "ATP6V0A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP6V0A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets